Business Context and Reporting Period
This Form 6-K filing by Addex Therapeutics Ltd. covers the month of June 2021, specifically dated June 29, 2021. The report discloses the entry into a material definitive agreement regarding a new equity offering program.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
Material Changes
On June 29, 2021, the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. Key terms include:
- Offering Size: The Company may offer and sell American Depositary Shares (ADSs) with an aggregate offering price of up to $16.0 million.
- Structure: Each ADS represents six (6) ordinary shares.
- Method: Sales will be conducted via an "at-the-market" offering program at the Company's sole discretion.
- Compensation: Cantor Fitzgerald will receive a commission of 3.0% of the gross sales proceeds.
- Obligation: The Company is not obligated to sell any ADSs under this agreement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard legal disclaimers regarding the securities offering. The agreement allows either party to suspend or terminate the offering upon notice. The Company retains the right to impose price, time, or size limits on sales.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the necessity of the $16.0 million ATM facility.
- Review the effective Form F-3 (No. 333-255089) referenced in the filing for the full registration details.
- Monitor future filings for actual sales volumes and pricing under the new agreement.
- Assess the potential dilution impact of issuing up to $16.0 million in ADSs.